R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 67.63
-0.99 (-1.44%)
At close: Apr 21, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 6.49 billion as of April 21, 2026. Its market cap has increased by 28.77% in one year.
Market Cap
6.49B
Enterprise Value
4.77B
Revenue
851.01M
Ranking
n/a
PE Ratio
47.29
Stock Price
67.63
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 6.49B, an increase of 20.21%. That is a compound annual growth rate of 5.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 20, 2026 | 6.59B | 16.26% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Wuhan Keqian Biology Co.,Ltd | 7.01B |
| Anhui Huaheng Biotechnology | 7.00B |
| Xiangxue Pharmaceutical | 6.83B |
| Beijing Scitop Bio-tech | 6.71B |
| Lifecome Biochemistry | 6.31B |
| Kexing Biopharm | 6.27B |
| Shenzhen Weiguang Biological Products | 6.21B |
| Shouyao Holdings (Beijing) Co., LTD. | 6.14B |